Aviragen Therapeutics Tops Q2 EPS by 11c
- ByInvesting.com-
Aviragen Therapeutics (AVIR) reported Q2 EPS of ($0.38), $0.11 better than the analyst estimate of ($0.49).
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Atea Pharmaceuticals Inc (AVIR)
NASDAQ
Symbol | Exchange | Currency |
|---|
8.38
-0.18(-2.10%)
After Hours
8.50
+0.12(+1.43%)
- Real-time Data
- Volume:238,507
- Day's Range:8.28 - 8.56
- 52 wk Range:5.31 - 46.91
AVIR Overview
- Prev. Close
- 8.56
- Day's Range
- 8.28-8.56
- Revenue
- 224.99M
- Open
- 8.56
- 52 wk Range
- 5.31-46.91
- EPS
- 0.187
- Volume
- 238,507
- Market Cap
- 697.71M
- Dividend (Yield)
- N/A(N/A)
- Average Vol. (3m)
- 597,824
- P/E Ratio
- 46.49
- Beta
- 0.566
- 1-Year Change
- -71.31%
- Shares Outstanding
- 83,258,603
- Next Earnings Date
- Nov 10, 2022
What is your sentiment on Atea?
or
Market is currently closed. Voting is open during market hours.
Atea Pharmaceuticals Inc News
- U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.56%
- ByInvesting.com-
Investing.com – U.S. stocks were higher after the close on Tuesday, as gains in the Healthcare, Utilities and Oil & Gas sectors led shares higher. At the close in NYSE, the Dow...
- Tesla Sales, Verizon 5G, IBM Earnings: 3 Things to Watch
- ByInvesting.com-
- 4
By Dhirendra TripathiInvesting.com -- Stocks rose on Tuesday on strong results from Johnson & Johnson and others that whet investors’ risk appetites.The S&P 500 was...
Atea Pharmaceuticals Inc Company Profile
Atea Pharmaceuticals Inc Company Profile
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, a novel antiviral agent that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 that is in Phase I/IIa clinical trial for the treatment of chronic hepatitis C; and AT-889, an investigational, second-generation nucleoside pyrimidine prodrug and other compounds for the treatment of respiratory syncytial virus. It has a Roche License Agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. for development and commercialization related to AT-527 outside of the United States. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Read More
Technical Summary
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Sell | Sell | Buy | Sell |
| Technical Indicators | Sell | Strong Buy | Strong Sell | Buy | Strong Sell |
| Summary | Neutral | Neutral | Strong Sell | Buy | Strong Sell |
Trending Stocks
Trending Stocks
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 65.22 | 65.35 | 64.71 | +0.34 | +0.52% | 6.49M | NYSE | |||
| 18.55 | 20.81 | 16.16 | -4.53 | -19.63% | 136.95M | NASDAQ | |||
| 367.99 | 369.94 | 362.75 | +3.30 | +0.90% | 1.96M | NYSE | |||
| 120.86 | 121.68 | 119.56 | +0.54 | +0.45% | 15.38M | NASDAQ | |||
| 245.17 | 246.48 | 239.28 | +4.02 | +1.67% | 5.27M | NASDAQ | |||
| 7.66 | 7.72 | 7.63 | +0.03 | +0.39% | 4.19M | NASDAQ | |||
| 53.55 | 53.72 | 53.04 | -0.21 | -0.39% | 10.31M | NYSE | |||
| 83.79 | 84.39 | 82.64 | +1.65 | +2.01% | 78.78K | NYSE | |||
| 173.05 | 175.14 | 171.58 | -2.29 | -1.31% | 4.23M | NYSE | |||
| 0.406 | 0.427 | 0.303 | +0.122 | +42.90% | 152.61M | NASDAQ | |||
| 266.58 | 267.36 | 265.42 | -0.24 | -0.09% | 1.59M | NYSE | |||
| 48.58 | 49.52 | 48.38 | -0.69 | -1.40% | 18.48M | NYSE | |||
| 68.14 | 68.16 | 67.63 | +0.45 | +0.66% | 215.05K | NYSE | |||
| 37.13 | 37.23 | 35.97 | +1.73 | +4.89% | 10.71M | NYSE | |||
| 94.02 | 99.91 | 93.22 | -10.40 | -9.96% | 5.16M | NYSE |
- Mar 15, 2022, 14:39whos following this garbage?
- Jan 30, 2022, 17:32It seems to me that there will be a short sqeeze here soon, I bought it for $ 6.77
- Nov 09, 2021, 23:50Avir must pump
- Nov 03, 2021, 03:45🚀🚀🚀
- Nov 03, 2021, 12:21???
- Oct 25, 2021, 16:53any comment ?
- Oct 20, 2021, 17:48AVIR (P) 0.00000000 42.98000000
- Oct 20, 2021, 17:09What is premkt volume?
- Oct 19, 2021, 23:39@ 14.01, 26 pt drop..why? what's the bad news. I feel like it's going up AMarket.Show previous replies (2)
- Oct 20, 2021, 17:05this is my business and from this i live.!
- Oct 22, 2021, 15:23what do you think about avir ?
- Oct 22, 2021, 15:39i know what will happen to Avir but i have to receive payment about this as i am expert and i am living from this. if you are willing to pay some fees i can give you my report for Avir and Prediction.
- Oct 19, 2021, 21:40?
- Oct 19, 2021, 20:03anybody around? What are yor feelings? Cheers.